Learn more about the Zepbound® savings card (no Gov`t beneficiaries, terms apply), the Zepbound cash option, and LillyDirect™, an online pharmacy solutions option.

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a …

Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. Zepbound should be used with a reduced- …

In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.

Dual-acting Zepbound is the only FDA-approved obesity management medication of its kind. It works differently by directly activating the receptors of GIP and GLP-1, two naturally occurring hormones. Learn about Zepbound and how it may help adults with obesity and adults with moderate-to-severe OSA and obesity:

INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe ...

Zepbound is a once-weekly injectable prescription medicine for chronic weight management in adults with an initial body mass index of at least 30 kg/m2 or at least 27 kg/m2 with at least one weight-related comorbid condition. It should be used along with a reduced calorie diet and increased physical activity.

Eli Lilly and Company has created a new self-pay pharmacy component of LillyDirect® where patients with a valid, on-label, electronic prescription from the health care provider of their choice can purchase Zepbound 2.5 and 5 mg vials. 1. Zepbound 2.5 and 5 mg vials are available.

INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.

Dec 5, 2023 · Following the U.S. Food and Drug Administration (FDA) approval on Nov. 8, 2023, people living with obesity can now access Zepbound in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) through a prescription that can be filled at retail and mail-order pharmacies.